免疫炎症参与冠心病发病，其具体靶点未明。申请人从临床视角出发开展T细胞与冠心病系列研究，主要学术业绩包括：①明确T细胞亚群（Th1/Th2/Treg/Th17）及相关因子在动脉粥样硬化中的作用，建立冠心病临床预警系统，创建检测血浆促炎因子预测冠脉斑块稳定性的方法；②提出“T细胞介导缺血心肌损伤”的新理论，阐明T细胞亚群（γδT /Treg）在缺血心肌损伤中的作用和机制，获批调控T细胞亚群化合物专利，为冠心病的免疫调节治疗提供新思路。近5年，申请人发表SCI论文41篇，其中以通讯或第一作者（含共同）在J Clin Invest, J Am Coll Cardiol等SCI杂志发表论文25篇（总IF 164.4分，其中4篇IF>10），SCI他引613次。申请人多年工作积累已形成稳定的研究体系，拟进一步细致研究T细胞在冠心病缺血后心室重塑中的效应机制及干预措施，为冠心病的临床防治提供新思路。

Immune inflammation is closely related to the pathogenesis of coronary artherosclerostic heart disease (CAD), but the mechanism is unclear. In recent years, we have concentrated on T cell and CAD from clinical perspective, mainly including: 1) We clarified the involvement of T cell subsets (Th1/Th2/Treg/Th17) and related cytokines in atherosclerosis, provided an early-warning system for CAD, and established a method to predict the stability of coronary artery plaque through detection of plasma inflammatory cytokines; 2) We came up with a new theory of “T cell mediating ischemic myocardial injury”, elucidated the role and mechanism of T cell subsets (γδT cells/Tregs) in ischemic myocardial injury, and designed a compound to regulate T cell differentiation, the patent authorization of which has been obtained. In the last 5 years, I have published 41 papers in journals such as J Clin Invest and J Am Coll Cardiol, including 25 papers as a corresponding/co-corresponding author or first/co-first author (total IF 164.4; 4 papers IF>10 ), the other-citing number is up to 613. Our research work has been forming a stable research system, and we will further study the role of T cell in ventricular remodeling after myocardial ischemia and provide innovative idea for prevention and treatment of CAD.